Table 2.
Serum and CSF NFL and GFAP levels
| Presymptomatic D-CAA n = 28 |
Symptomatic D-CAA n = 29 |
Sporadic CAA n = 59 |
Controls <55 y n = 33 |
Controls ≥55 y n = 38 |
|
|---|---|---|---|---|---|
| Serum NFL (pg/mL)a | 6.72 (3.28 - 49.50) | 26.20 (4.61 - 123.43) | 25.56 (7.39 - 159.74) | 7.78 (1.88 - 97.97) | 12.46 (6.28 - 83.59) |
| CSF NFL*102 (pg/mL)b | 4.34 (2.30 - 11.54) | 16.80 (6.06 - 79.23) | 20.00 (7.36 - 95.79) | 3.63 (2.14 - 11.47) | 7.76 (3.76 - 15.72) |
| Serum GFAP (pg/mL)c | 66.03 (20.16 - 150.46) | 130.75 (51.21 - 358.70) | 177.89 (51.18 - 436.01) | 60.75 (14.45 - 218.84) | 123.37 (38.82 - 320.52) |
| CSF GFAP*103 (pg/mL)d | 7.69 (3.46 - 11.03) | 11.41 (5.87 - 26.50) | 10.93 (3.48 - 32.01) | 4.44 (0.77 - 7.98) | 7.51 (1.19 - 14.99) |
aPresymptomatic participants with D-CAA n=28, symptomatic participants with D-CAA n=28, sCAA participants n=56, controls <55 n=29, controls ≥55 n=37
bPresymptomatic participants with D-CAA n=10, symptomatic participants with D-CAA n=12, sCAA participants n=28, controls <55 n=31, controls ≥55 n=18
cPresymptomatic participants with D-CAA n=25, symptomatic participants with D-CAA n=26, sCAA participants n=51, controls <55 n=31, controls ≥55 n=34
dPresymptomatic participants with D-CAA n=11, symptomatic participants with D-CAA n=12, sCAA participants n=28, controls <55 n=32, controls ≥55 n=20
Abbreviations: CAA cerebral amyloid angiopathy, CSF cerebrospinal fluid, NFL neurofilament light chain, D-CAA Dutch Cerebral Amyloid Angiopathy, GFAP glial fibrillary acidic protein, y years